CELG $68.20 -1.54 (-2.21%)
Fri, Dec 14, 2018
Celgene Corp is a Health Care stock that trades on the NASDAQ with a market cap of $63.95 Billion
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline. http://www.celgene.com
If you haven't signed up for Ebates yet, you are definitely leaving money on the table.
Get up to 12% CASH BACK from shopping @ $AMZN, $WMT and $EBAY & $10 Sign Up Bonus (through this link)!
Celgene Corp Stock Charts
The 5 year and 1 year stock charts are below.
50 Day Moving Average
The 50 Day Moving Average is at $74.49 which is 8.44% above the stock price of $68.20.
200 Day Moving Average
The 200 Day Moving Average is at 83.31 which is 18.14% abovethe stock price of $68.20.
Because both the 50 DMA and 200 DMA are above the current stock price, this can be considered a bearish technical indicator.
CELG Stock Price
Below are a few key dates for the stock price.
Year To Date
The most recent stock price is $68.20.
The Year To Date (YTD) return is -35.76%.
52 Week Low
The 52 Week Low stock price is $66.65 set on Fri, Nov 23, 2018 which is 23 days ago.
The current price per share is 2.33% above the 52 week low.
52 Week High
The 52 Week High stock price is $109.41 set on Fri, Dec 15, 2017 which is 366 days ago.
The current price per share is -37.67% below the 52 week high.
All Time High
The All Time High stock price is $146.52 set on Wed, Oct 4, 2017 which is 438 days ago.
The current price per share is -53.45% below the all time high.
Below is the EPS, P/E Ratio and Earnings Date.
The Earnings Per Share (EPS) is $1.54.
The Price To Earnings (P/E) Ratio is 17.70.
Celgene Corp has a relatively low price to earnings ratio compared to the overal S&P 500 average, which is about 25%.
Some investors look for very low p/e stocks with the hopes of investing in an undervalued stock. Of course, this is just one factor to consider.
Stocks can make big percentage moves on the earnings announcement.
Companies announce earnings either before the market open or after the close.
The Earnings Release Date for Celgene Corp was Thu, Jul 26, 2018.
Since this earnings release 143 days ago, the stock price is down by -22.21%.
Many investors know the importance of a companies earnings report. Also, the market reaction to the earnings release can be even more important and can help in making a prediction of a future price forecast of the shares.
A significant post earnings announcement percentage move can continue or reverse an existing trend for several days or weeks after the earnings date.
The most recent Earnings Release Date was on Thu, Oct 25, 2018, which was 52 days ago.
Since this earnings date, the stock price is down by -8.71%.
Celgene Corp Dividend
Below is important Dividend information.
CELG currently does not pay a dividend.
You may like this list of best dividend stocks of 2018.
Below are some other Biotech & Pharma industry stocks like Celgene Corp.